BACKGROUND: Drug-eluting stents have been used in daily practice since 2002, with the clear advantages of reducing the risk of target vessel revascularization and an impressive reduction in restenosis rate by 50%-70%. However, the occurrence of a late thrombosis can compromise long-term results, particularly if the risks of this event were sustained. In this context, a registry of clinical cases gains special value. OBJECTIVE: To evaluate the efficacy and safety of drug-eluting stents in the real world. METHODS: We report on the clinical findings and 8-year follow-up parameters of all patients that underwent percutaneous coronary intervention with a drug-eluting stent from January 2002 to April 2007. Drug-eluting stents were used in accordance with the clinical and interventional cardiologist decision and availability of the stent. RESULTS: A total of 611 patients were included, and clinical follow-up of up to 8 years was obtained for 96.2% of the patients. Total mortality was 8.7% and nonfatal infarctions occurred in 4.3% of the cases. Target vessel revascularization occurred in 12.4% of the cases, and target lesion revascularization occurred in 8% of the cases. The rate of stent thrombosis was 2.1%. There were no new episodes of stent thrombosis after the fifth year of follow-up. Comparative subanalysis showed no outcome differences between the different types of stents used, including Cypher®, Taxus®, and Endeavor®. CONCLUSION: These findings indicate that drug-eluting stents remain safe and effective at very long-term follow-up. Patients in the "real world" may benefit from drug-eluting stenting with excellent, long-term results.
BACKGROUND: Drug-eluting stents have been used in daily practice since 2002, with the clear advantages of reducing the risk of target vessel revascularization and an impressive reduction in restenosis rate by 50%-70%. However, the occurrence of a late thrombosis can compromise long-term results, particularly if the risks of this event were sustained. In this context, a registry of clinical cases gains special value. OBJECTIVE: To evaluate the efficacy and safety of drug-eluting stents in the real world. METHODS: We report on the clinical findings and 8-year follow-up parameters of all patients that underwent percutaneous coronary intervention with a drug-eluting stent from January 2002 to April 2007. Drug-eluting stents were used in accordance with the clinical and interventional cardiologist decision and availability of the stent. RESULTS: A total of 611 patients were included, and clinical follow-up of up to 8 years was obtained for 96.2% of the patients. Total mortality was 8.7% and nonfatal infarctions occurred in 4.3% of the cases. Target vessel revascularization occurred in 12.4% of the cases, and target lesion revascularization occurred in 8% of the cases. The rate of stent thrombosis was 2.1%. There were no new episodes of stent thrombosis after the fifth year of follow-up. Comparative subanalysis showed no outcome differences between the different types of stents used, including Cypher®, Taxus®, and Endeavor®. CONCLUSION: These findings indicate that drug-eluting stents remain safe and effective at very long-term follow-up. Patients in the "real world" may benefit from drug-eluting stenting with excellent, long-term results.
Authors: Alexandra Theresia Fuchs; Andreas Kuehnl; Jaroslav Pelisek; Pierre Henri Rolland; Choukri Mekkaoui; Heinrich Netz; Sigrid Nikol Journal: Endothelium Date: 2008 Jan-Feb
Authors: Keith D Dawkins; Eberhard Grube; Giulio Guagliumi; Adrian P Banning; Krzysztof Zmudka; Antonio Colombo; Leif Thuesen; Karl Hauptman; Jean Marco; William Wijns; Jeffrey J Popma; Joerg Koglin; Mary E Russell Journal: Circulation Date: 2005-11-14 Impact factor: 29.690
Authors: Bruce Brodie; Yashashwi Pokharel; Nathan Fleishman; Adam Bensimhon; Grace Kissling; Charles Hansen; Sally Milks; Michael Cooper; Christopher McAlhany; Tom Stuckey Journal: JACC Cardiovasc Interv Date: 2011-01 Impact factor: 11.195
Authors: Martin B Leon; Eugenia Nikolsky; Donald E Cutlip; Laura Mauri; Henry Liberman; Hadley Wilson; John Patterson; Jeffrey Moses; David E Kandzari Journal: JACC Cardiovasc Interv Date: 2010-10 Impact factor: 11.195
Authors: Francesco Saia; Giancarlo Piovaccari; Antonio Manari; Paolo Guastaroba; Luigi Vignali; Elisabetta Varani; Andrea Santarelli; Alberto Benassi; Armando Liso; Gianluca Campo; Stefano Tondi; Fabio Tarantino; Rossana De Palma; Antonio Marzocchi Journal: EuroIntervention Date: 2009-05 Impact factor: 6.534
Authors: Pedro A Lemos; Angela Hoye; Dick Goedhart; Chourmouzios A Arampatzis; Francesco Saia; Willem J van der Giessen; Eugene McFadden; Georgios Sianos; Pieter C Smits; Sjoerd H Hofma; Pim J de Feyter; Ron T van Domburg; Patrick W Serruys Journal: Circulation Date: 2004-03-01 Impact factor: 29.690
Authors: Sripal Bangalore; Sunil Kumar; Mario Fusaro; Nicholas Amoroso; Michael J Attubato; Frederick Feit; Deepak L Bhatt; James Slater Journal: Circulation Date: 2012-05-14 Impact factor: 29.690
Authors: Sripal Bangalore; Sunil Kumar; Mario Fusaro; Nicholas Amoroso; Ajay J Kirtane; Robert A Byrne; David O Williams; James Slater; Donald E Cutlip; Frederick Feit Journal: BMJ Date: 2012-08-10